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ABSTRACT
5-Aza-20-deoxycytidine (5-azadC) is a DNA
methyltransferase (DNMT) inhibitor increasingly
used in treatments of hematological diseases and
works by being incorporated into DNA and
trapping DNMT. It is unclear what DNA lesions are
caused by 5-azadC and if such are substrates for
DNA repair. Here, we identify that 5-azadC induces
DNA damage as measured by c-H2AX and 53BP1
foci. Furthermore, 5-azadC induces radial chromo-
somes and chromatid breaks that depend on active
replication, which altogether suggest that trapped
DNMT collapses oncoming replication forks
into double-strand breaks. We demonstrate that
RAD51-mediated homologous recombination (HR)
is activated to repair 5-azadC collapsed replication
forks. Fanconi anemia (FA) is a rare autosomal
recessive disorder, and deaths are often associated
with leukemia. Here, we show that FANCG-deficient
cells fail to trigger HR-mediated repair of 5-azadC-
induced lesions, leading to accumulation of chro-
matid breaks and inter-chromosomal radial fusions
as well as hypersensitivity to the cytotoxic effects
of 5-azadC. These data demonstrate that the FA
pathway is important to protect from 5-azadC-
induced toxicity. Altogether, our data demonstrate
that cytotoxicity of the epigenetic drug 5-azadC can,
at least in part, be explained by collapsed replication
forks requiring FA-mediated HR for repair.
INTRODUCTION
DNA methylation is controlled by a family of DNA
methyltransferases (DNMT), enzymes that catalyze the
transfer of a methyl moiety from S-adenosyl-l-methionine
to the 5-position of cytosines in the CpG dinucleotide to si-
lence gene expression (1). When entering the cell, 5-aza-20-
deoxycytidine (5-azadC) is phosphorylated to 5-azadCTP
and incorporated into DNA during replication. As a result
of the chemistry of the methyltrasferase reaction, the
DNMT becomes covalently linked to DNA, in effect
creating a protein–DNA cross-link (2–5). This results in
depletion of soluble DNMT protein levels, which induces
replication-dependent global demethylation and gene
reactivation (6). Although there is a considerable amount
of literature regarding the possible anti-cancer mode of
action of 5-azadC, the molecular mechanism of cell
death still remains unclear. There are two non-exclusive
models: one involves the reactivation of silenced genes
involved in cell growth, which is accompanied by cell
cycle arrest and/or apoptosis (7). Another model empha-
sizes the importance of the formation of covalent DNMT–
DNA adducts, which leads to DNA damage and cytotox-
icity (3,8).
Epigenetic targets such as DNMT has become a
promising new strategy for cancer treatments, especially
hematologic malignancies such as myelodysplastic syn-
dromes and acute myeloid leukemia (AML) (9,10).
Many anti-cancer therapies are cytotoxicity based on
their ability to cause DNA damage, e.g. ionizing radiation
or chemotherapy drugs. The 5-azadC is a nucleoside
analogue that when is incorporated into newly synthesized
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DNA, results in covalent trapping of DNMTs causing
genome-wide protein–DNA cross links (2–5).
Fanconi anemia (FA) is a rare autosomal recessive
disorder characterized by progressive pancytopenia,
requiring bone marrow transplant, and associated con-
genital abnormalities, such as microcephaly, short
stature, skeletal, cardiac and renal malformations.
Mortality is associated with bone marrow failure and
leukemia in the first 2 decades of life, with the majority
of deaths occurring within 5 years after the onset of
anemia (11,12). The disease is caused by mutations
within a variety of genes associated with the FA
pathway. Many genes have been linked in the pathogen-
esis of FA, and at least 15 genes, including a nine-gene FA
nuclear core complex with associated downstream
proteins, all function to promote genetic stability via
repair of DNA following damage (13). One of these
genes is the well-known breast cancer susceptibility gene
BRCA2, while mutations in others such as PALB2,
RAD51C or BRIP1 also pre-dispose to cancer. Germline
mutations of these genes are associated with dysregulation
of cell cycle and apoptosis (14,15), and chromosomal
instability (14). It has been postulated that disruption of
the FA complex and associated pathways are related
with chromosomal and telomere instability characterized
by impaired DNA double-strand break (DSB) repair
leading to the inactivation of tumor suppressor genes
and activation of oncogenes (16). The FA pathway in
normal cells is not constitutively active but is inactivated
by genetic or epigenetic mechanisms in a variety of
cancers, including breast, ovarian, head and neck,
cervical, pancreatic and lung carcinomas, rendering the
affected tumors potentially hypersensitive to DNA cross-
linking agents (17).
Here, we report that 5-azadC induces DNA damage that
depends on active replication, which suggests that trapped
DNMT collapses with oncoming replication forks into
DSBs. We demonstrate that RAD51-mediated homolo-
gous recombination (HR) is involved in the repair of
such DSBs, a process that is defective in FA cells. This
agrees with a reduced cell survival and a potentiation of
chromosomal abnormalities. To strengthen this, we also
show that proteasome inhibition sensitizes against
5-azadC in wild-type, but not in FA cells. Furthermore,
we report a preferential protection in FA cells when non-
homologous end joining (NHEJ) inhibitors were used.
MATERIALS AND METHODS
Chemicals
The 5-azadC, aphidicolin (APH), NU7026 and MG132
were purchased from Sigma and diluted in dimethyl
sulfoxide except 5-azadC that was diluted in phosphate
buffered saline (PBS) (10mM sodium phosphate (pH
7.4), 140mM NaCl and 3mM KCl). All of them were
aliquoted and stored at 80C before use.
Cell culture
The parental Chinese hamster ovary cell line AA8 was
purchased from the American Type Culture Collection
(ATCC), USA. The isogenic FANCG-deficient Chinese
hamster ovary mutant KO40, derived from AA8, was
kindly provided by Dr. Fabrizio Palitti (Department of
Agrobiology and Agrochemistry, University of Tucsia,
Viterbo, Italy) and has been previously described (18).
Cells were routinely maintained as monolayers in
McCoy’s 5A media (LONZA) supplemented with 10%
fetal bovine serum, 2mM L-glutamine and the antibiotics
penicillin (50U/ml) and streptomycin (50mg/ml).
Cells were cultured at 37C in an atmosphere containing
5% CO2.
Colony formation
Cell survival following 5-azadC treatment was measured
by clonogenic assay. AA8 and KO40 cells were plated at
low density onto 10 cm Petri dishes. After 4 h, cultures
were incubated for 24 h (two rounds of DNA replication
approximately) in the presence of different concentrations
of 5-azadC (1, 3.25, 7.5 and 15 mM). For combined experi-
ments (5-azadC+inhibitor), cells were treated for 24 h
with the NHEJ inhibitor NU7026 (10mM) or the prote-
asome inhibitor MG132 (0.1 mM), respectively. These
doses were chosen on the basis of its absence of cellular
cytotoxicity. Then 5-azadC was discarded, and the
cultures were further incubated for 24 h with each one of
the inhibitors. After that, fresh media was added, and cells
were allowed to grow from 7 to 10 days. Colonies were
stained with methylene blue prepared in methanol (4 g/l).
Surviving colonies made up of >50 cells per colony were
counted. The data have been corrected according to
cloning efficiencies of control cells.
Chromosome analysis
Exponential growing AA8 or KO40 cells were cultured for
24 h in the presence of different concentrations of 5-azadC
(3.25, 7.5 and 15 mM). After that, cells were incubated with
fresh media for 12 h before mitotic arrest. For combined
experiments (5-azadC+APH), cells were treated for 12 h
with 5-azadC. After that, cells were thoroughly washed
and 0.5 mM of APH was added for a further 12 h. Then,
APH was discarded, and cultures were allowed to recover
in fresh media for 6 h until the addition of colcemid to
arrest cells in metaphase. To prepare metaphase spreads,
cells were treated with 2 107M of colcemid for 2 h and
30min. Cells were collected and incubated in hypotonic
solution (0.075M KCl) for 2min, fixed in methanol: acetic
acid (3:1) and dropped onto microscope slides. Slides were
stained with 3% Giemsa/So¨rensen’s buffer for 5min and
mounted in D.P.X. (Sigma). Two hundred complete meta-
phases were evaluated in each experimental point. Images
were taken with a Nikon eclipse 50i microscope equipped
with a Nikon DS-Fi1 camera and using the 100-fold mag-
nification objective (numerical aperture 1.25) and the NIS
Elements 3.0 adquisition software (Nikon).
To visualize sister chromatid exchanges (SCE), cells
were incubated with 10 mM of bromodeoxyuridine
(BrdU, Sigma) along with increasing doses of 5-azadC
(0.25, 0.5 and 1 mM) for 24 h. Then, cells were washed
and allowed to repair for 12 h before addition of
colcemid. Differential staining of BrdU-substituted sister
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chromatids was obtained by the fluorescence-plus-Giemsa
technique as reported elsewhere (19).
Immunofluorescence labeling and microscopy
(Foci detection)
Cells were seeded on coverslips the day before being
treated with 5-azadC (0.25, 0.5 and 1 mM) for 24 h. After
that, cells were washed with PBS and incubated for 30 s
with cold 0.1% Triton X-100 in PBS to pre-extract soluble
protein unlocated in foci. Afterwards, cells were fixed with
4% formaldehyde in PBS for 10min at room temperature.
The primary antibodies used were a rabbit polyclonal
antibody a-RAD51 (H-92, Santa Cruz) or a-53BP1
(H-300, Santa Cruz) and a mouse monoclonal a-gH2AX
(Upstate). Secondary fluorescent antibodies were an Alexa
fluor 488-conjugated goat anti-mouse and an Alexa fluor
555-conjugated goat anti-rabbit (Invitrogen). DNA was
stained with 100 nM of 4,6 diamidino-2-phenylindole
for 15min. Slides were mounted in anti-fade media
(Vectashield). Immunofluorescence was observed using a
Nikon eclipse 50i microscope with a 40-fold magnification
objective. Cells with 10 foci were scored as positive.
At least 200 nuclei were analyzed for each treatment.
Micrographs were taken using a Leica AF6000 micro-
scope equipped with a Leica DFC 350 FX camera and
using the Application Suite Advanced Fluorescence
adquisition software (Leica) and a 63-fold magnification
objective (numerical aperture 1.4). Images were bright-
contrast processed using Adobe Photoshop 5.0 software
(Adobe).
Statistical analysis
For the determination of significance of the difference
between the means, Student’s t-test was used. Statistical
treatment and plotting of the results were performed using
the Sigma Plot and MS Excel for Windows XP software.
The results come from at least two independent experi-
ments and are presented as mean±standard deviation
(SD) of the mean. Differences were considered significant
when *P< 0.05 or **P< 0.01.
RESULTS
5-azadC causes replication-dependent strand breaks
resulting in chromatid breaks and radial fusion
chromosomes
It has been previously shown that cytoxicity of 5-azadC to
mammalian cells can be mediated through covalent
DNMT-DNA adducts, which in turn cause DNA damage
that activates ATR signaling (3,20). Here, we find that
5-azadC treatment produces g-H2AX foci (Figure 1A and
B), which has also been reported earlier (3). It is established
that g-H2AX foci can form also in the absence of DSBs
(21), whereas 53BP1 foci formation are more strictly
associated with DSBs. Here, we find that 5-azadC also
induces 53BP1 foci (Figure 1A and C), suggesting that
DSBs may be formed after 5-azadC treatments.
DSBs are highly toxic and may cause chromatid breaks
if they persist into mitosis or radial-fusion chromosomes if
chromatid breaks are aberrantly repaired. Figure 1D–G
shows that control metaphases showed only low percent-
ages of abnormalities, whereas 5-azadC treatment induced
an increase in chromosomal aberrations, including chro-
matid breaks and radial chromosomes, which may explain
toxic effects caused by 5-azadC.
Furthermore, we wanted to determine how 5-azadC
may cause DSBs and chromatid breaks. A lack of induc-
tion of isochromatid breaks (data not shown) seems to
indicate that 5-azadC behave as a typical S-phase depend-
ent agent. In hypothesis, trapped DNMT may obstruct
replication forks causing replication collapse and DSBs.
It is well documented that replication-blocking DNA
lesions can cause replication fork collapse and thereby
lead to the formation of DNA DSBs (22). To test this,
we determined chromosome damage by 5-azadC while
transiently inhibiting DNA synthesis using APH, using a
dose previously shown to completely inhibit replication
progression in the same cells (23), to test whether the chro-
matid breaks were a result of collapsed replication forks.
We found a decreased amount of chromatid breaks
in agreement with this hypothesis (Figure 1H). Overall,
our findings are in line with a hypothesis that 5-azadC-
induced DSBs arising as a consequence of trapped DNMT
collapses oncoming replication forks into DSBs.
Repair of 5-azaC induced DSBs requires HR
Our data suggest that DSBs arising as a consequence of
5-azadC incorporation are generated during the second
round of DNA replication. It is well accepted that repli-
cation-induced DSBs are potent substrates for HR giving
rise to RAD51-mediated SCEs formation (24–26). To test
this directly, we treated cells with increasing doses of
5-azadC and scored SCEs or RAD51 foci formation.
We found that the frequency of SCEs is increased after
treatment with 5-azadC (Figure 2A). Furthermore,
we also find an increase in RAD51 foci formation
(Figure 2B and C), which altogether support a model
where replication forks collapsed by DNMT–DNA
adducts trigger HR for repair. Furthermore, cells deficient
in BRCA2, a protein that interacts with RAD51 and
promotes its loading to single-stranded DNA, are hyper-
sensitive to the toxic lesions induced by 5-azadC
(Supplementary Figure S1).
FANCG-mediated HR is required for 5-azadC survival
The FA proteins are known to play a critical role in repair
at obstructed replication forks, especially of crosslinks (27).
Here, we tested 5-azadC sensitivity in the absence the FA
core complex using the FANCGmutant KO40 cell line (18).
Results show that KO40 cells were more sensitive to
5-azadC treatment, with a significant decrease in cell
survival to all doses tested compared with its isogenic and
parental cell line AA8. The sensitization ranged from
2 to 10 times for the doses of 3.25 to 15 mM, respectively
(Figure 3A). These results demonstrate that FANCG-
deficient cells are sensitive to 5-azadC-mediated cytotox-
icity. Furthermore, using human fibroblasts deficient
in FANCD2, a central key protein of the FA pathway, we
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found that they were also sensitive to 5-azadC as compared
with corrected cells (Supplementary Figure S2).
To test the molecular reason for the increased toxicity
of FANCG-deficient cells, we determined the amount of
DNA lesions induced by 5-azadC in KO40 and AA8 cells.
Both AA8 and KO40 cells showed the same amount of
increase of g-H2AX and 53BP1 foci on 5-azadC treatment
(Figure 3B and C), suggesting that the lesions are
produced irrespectively of FA status.
Next, we wanted to asses whether the differences
observed in survival could be the result of the HR repair
defects in FANCG-deficient cells. Here, we found clear dif-
ferences between AA8 and KO40 in the yield of SCEs
induced by 5-azadC, where only the WT AA8 cells are
able to induce SCE and the KO40 cells are defective in
5-azadC-induced HR (Figure 3D). The same results were
obtained when we evaluate the residual foci formation
of RAD51 as a marker of HR after 5-azadC treatment
Figure 1. DNA damage induced by 5-azadC. (A) DNA damage response induced by 5-azadC. AA8 cells were grown on coverslips, treated with
5-azadC for 24 h (1.5 mM) and fixed for analysis of nuclear g-H2AX or 53BP1 foci by inmunofluorescence. Original magnification 630X.
Quantification of g-H2AX (B) or 53BP1 (C) foci was evaluated in 200 nuclei for each treatment. Cells with 10 foci were scored as positive.
(D and E) Chromosomal abnormalities induced by 5-azadC. Exponential growing AA8 cells were cultured for 24 h in the presence of 5-azadC
(15mM), washed and allowed to recover for 12 h before mitotic arrest. Two hundred metaphases were analyzed for chromosomal abnormalities
in each experimental point. Representative micrographs of AA8 metaphases treated with 5-azadC (7.5 mM). Arrows point to a chromatid break (D)
and a radial fusion chromosome (E). Original magnification 1000X. Their respective quantifications are plotted on (F and G). (H) Influence of APH
on the induction of chromatid breaks by 5-azadC. AA8 cells were treated for 12 h with 5-azadC (15 mM), washed and allowed to repair in free media
or in media containing APH (0.5 mM) for 12 h as described in ‘Materials and Methods’ section. Each bar represents the mean and the SD from three
independent experiments. Differences were statistically significant (*P< 0.05, **P< 0.01 according Student’s t-test).
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(Figure 3E). Overall, these data revealed that FA pathway
promotes the repair of DNA lesions induced by 5-azadC by
a process mediated by HR.
Next, we tested chromosome analysis on AA8 andKO40
cells cultured in the presence of 5-azadC. Control meta-
phases showed only low percentages of abnormalities
(Figure 4A and B). Concerning 5-azadC treatment, there
was a dose-dependent increase in chromosomal aberra-
tions, including chromatid breaks and radial chromosomes
for both AA8 and KO40 cells. However, only FANCG-
deficient cells showed a dramatic increase in chromosome
aberrations as compared with the parental cells AA8.
Metaphases of KO40 treated with the highest dose of
5-azadC showed severe aberrations (Figure 4A and B).
We also wanted to determine whether the increase in chro-
matid breaks and radial chromosomes were of the same
origin, as the one occurring in wild-type cells, that is,
derived following replication. To test this, 5-azadC-
treated cells were washed and treated with APH, which
prevents the subsequent collision of replication forks with
DNMT–DNA adducts. We found that the 5-azadC-
induced chromatid breaks and radial fusion chromosomes
were reversed by preventing replication forks collide into
the DNMT-trapped complex on DNA (Figure 4C and D).
Altogether, these data suggest that the FA pathway is
involved in HR repair of replication-associated DSBs
formed after collapse of replication forks that are ob-
structed by DNMT–DNA adducts. Failed repair leads to
chromatid breaks and formation of radial chromosomes.
Proteasome inhibitor MG132 sensitizes wild-type, but not
FA defective cells to 5-azadC
Previous reports have shown that proteasome function
is required for activation of the FA pathway (28), as
well as to catalyze HR (29). To test whether proteasome
inhibition affects 5-azadC induced cell death, combined
experiments were performed where AA8 and KO40 cells
were co-treated with the proteasome inhibitor MG132
at non-toxic dose (Supplementary Figure S3). MG132
sensitized AA8 cells treated with 5-azadC to a similar
level as observed in FA cells (Figure 5A). The sensitization
effect was 2.5-fold across all doses used (Figure 5B).
Interestingly, no evidence of sensitization was observed
for KO40 cells, and hence an epistatic effect is observed
Figure 2. The 5-azadC induces lesions that are repaired by HR. (A) SCEs in AA8 cells after a 24 h treatment with 5-azadC (1 mM). Cells were
incubated with 10 mM of BrdU in the 5-azadC for two cell cycles, washed and allowed to repair for 12 h before metaphase arrest. Differential staining
of BrdU-substituted sister chromatids was obtained by fluorescence-plus-Giemsa technique. A number of 50 complete metaphases with well-preserved
chromosome morphology were scored from two independent experiments. (B) The 5-azadC induced RAD51 foci in AA8 cells. Cells growing on
coverslips were treated with 5-azadC (1mM) for 24 h and fixed for analysis of nuclear RAD51 foci by inmunofluorescence. Foci were evaluated in 200
nuclei per treatment. Cells with 10 foci were scored as positive. Each bar represents the mean and the SD from three independent experiments.
Differences were statistically significant (*P< 0.05, **P< 0.01 according Student’s t-test). (C) Representative micrographs of either control and
5-azadC-treated AA8 cells showing RAD51 foci.
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between FANCG and the proteasome inhibitor MG132.
This finding demonstrates that proteasome is required to
promote cell survival after 5-azadC treatment. Also, the
data point to that, directly or undirectly, proteasome and
FA pathway work in the same pathway to promote
survival. Overall, these data also strengthen the overall
finding that FA-mediated HR is required for survival
after 5-azadC treatment.
DNA-protein kinase inhibition protects from the
deleterious effect induced by 5-azadC
It is well accepted that HR repairs a broader spectrum of
lesions that occur at stalled replication forks, whereas
NHEJ is believed to have a more important role in the
repair of two-ended DSBs (30,31). However, the relation-
ship between HR and NHEJ is complex, and it has previ-
ously been demonstrated that the repair defect in FA cells
reverts by inhibition of DNA-protein kinase and that the
cells then are no longer sensitive to crosslinkers (32). The
underlying mechanism is not entirely clear, but it is
possible that inhibition of NHEJ prevent error-prone
repair, which can be toxic.
Here, we used the DNA-protein kinase inhibitor
NU7026 to test whether inhibition of NHEJ affects the
response to 5-azadC. Interestingly, we show an increase
in cell survival in both AA8 and KO40 cells after treatment
with 5-azadC (Figure 6A) in the presence of a non-toxic
dose of NU7026 (Supplementary Figure S3), compared
with those cells that received only the treatment with
5-azadC. Also, we show that the increase in cell survival
(represented as fold increase) was clearly higher for
FANCG-deficient cells than for AA8 cells (Figure 6B).
Furthermore, the sensitization effect was increased with
increasing doses (Figure 6B). Our findings are consistent
with the interpretation given by others (32) that FA
protects from the promiscuous action of NHEJ during the
repair of lesions induced by crosslink agents. In this respect,
the severe cytotoxicity that 5-azaC produced in KO40 cells
can be significantly suppressed by inhibiting NHEJ.
DISCUSSION
The 5-azadC (decitabine) and 5-azaC (azacitidine) are ex-
tensively used in myelodysplastic syndrome treatment and
increasingly used in experimental treatment of AML
(9,10). Both are inhibitors of DNMT, but the cytotoxic
mechanism remains somewhat unclear and can involve
both activation of apoptosis and DNA damage. Here,
we confirm earlier findings that 5-azadC causes g-H2AX
foci (3,20), which is a general marker for DNA damage
and not specific for DSBs. Adding to this, we observe that
53BP1 foci are induced by 5-azadC treatment, which is a
more stringent marker for DSBs. Also, we observe an
increase in chromatid breaks and radial chromosomes,
which if left unrepaired are toxic to cells. Altogether,
our data strongly suggest that DSB formation is formed
after 5-azadC treatment. The next question is how DSB
may form after 5-azadC treatment? It is well established
that DNMT is covalently linked to DNA on 5-azadC
treatment (2–5), which may become an obstacle during
DNA replication, which could lead to collapse of replica-
tion forks and DSBs. It is well established that the topo-
isomerase I poison camptothecin traps topoisomerase I
onto DNA, which is converted to a DSB at replication
forks (26,33), which in turn trigger HR for repair (26).
In analogy, we use APH to stop ongoing replication in
cells with incorporated 5-azadC that traps DNMT, to
test whether this would reduce the amount of chromatid
breaks. Indeed, we observe that the number of chromatid
breaks is reduced, demonstrating that the toxic DSBs
formed after 5-azadC treatment requires ongoing replica-
tion. These data suggest that 5-azadC causes replication
collapse to form DSBs. Normally, such breaks are
repaired by RAD51-mediated HR to repair and restart
Figure 3. Cells deficient in the FA pathway are hypersensitive to
5-azadC. (A) Cell survival after a 24 h treatment with increasing con-
centrations of 5-azadC. AA8 and KO40 cells were seeded on Petri
dishes and allowed to attach for 4 h; subsequently, they were treated
with increasing concentrations of 5-azadC. Then media was changed
and cells were allowed to form colonies. (B and C) Quantification of g-
H2AX and 53BP1 foci in AA8 and KO40 cells after 24 h treatment
with increasing concentrations of 5-azadC. (D) Differential induction of
SCEs by 5-azadC in AA8 and KO40 cells. Cells were treated with
10 mM BrdU together with increasing concentrations of 5-azadC
(0.25–1mM) as described in ‘Materials and Methods’ section.
(E) RAD51 foci formation in AA8 and KO40 cells after 24 h of
5-azadC treatment. Data show the mean and the SD from 2–3 inde-
pendent experiments. Differences were statistically significant
(*P< 0.05, **P< 0.01 according Student’s t-test).
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replication (34), which leaves an SCE (26). Our data
strongly suggest that HR is activated to repair 5-azadC
lesions as both RAD51 foci, and SCEs are induced by this
treatment. This is further strengthen by the observation
that KO40 cells, defective in FANCG, which is required
for HR repair at collapsed replication forks (18), are
hypersensitive to 5-azadC treatment and cannot trigger
RAD51-mediated repair and fail to induce SCEs. We
observe an increase in unrepaired chromatid breaks in
FANCG defective cells, which is the logical consequence
by failure to activate HR repair. We also observe an
increase in radial chromosomes in FANCG defective
cells, clearly demonstrating the link between unrepaired
chromatid breaks and the formation of radial chromo-
somes. In absence of HR, it is highly likely that NHEJ
will eventually fuse DSBs. If breaks occur at replication
forks, only single DNA ends would be present and fusion
with another end would result in formation of chromo-
some aberrations, such as radial chromosomes.
Altogether, our data point to a model to explain the
effects of 5-azadC, where incorporated 5-azadC traps
DNMT onto DNA, which becomes an obstacle to the
second round of replication and results in a collapsed
replication fork with a DSB (Figure 7). Such replication-
associated DSB is normally repaired by RAD51-mediated
HR, which results in an SCE. However, in absence of
repair, chromatid breaks accumulate, and NHEJ fuses
DNA ends that results in radial chromosomes, which
will break during mitosis (Figure 7).
It is well established that proteasome inhibitors impair
both the activation of FA pathway (28), as well as to
catalyze HR (29). The likely mechanism is that the FA
pathway requires a mono- ubiquitination of the
FANCD2 and FANCI subunits to promote HR repair
(35). Similarly, the HR pathway requires RNF8
mediated ubiquitination to promote HR repair (36).
As proteasome inhibitors prevent degradation of ubiquiti-
nated proteins, the level of free ubiquitin is rapidly
depleted in cells, which will impair both FA and HR
pathways. Here, we found that the proteasome inhibitor
MG132 potentiate the toxic effects of 5-azadC treatment
only in wild-type AA8 cells, but not in the FANCG-defect-
ive cells. This can be explained by HR is impaired by
MG132 in wild-type cells, which increase the sensitivity
of 5-azadC to the same level as the FANCG-defective
cells. As the proteasome inhibitor does not potentiate
Figure 4. Deffects in the FA pathway potentiate the level of chromosome abnormalities induced by 5-azadC. (A and B) Quantification of chromatid
breaks and radial fusion chromosomes in AA8 and KO40 cells. Cells were treated for 24 h with increasing concentrations of 5-azadC, washed and
allowed to repair for 12 h before mitotic arrest. To test whether the induction of chromosome aberrations has the same origin in both cell lines, we
analyzed the effect of replication inhibition by APH (0.5 mM) on the levels of chromatid breaks (C) and radial fusion chromosomes (D). Exponential
AA8 and KO40 cells were treated with 5-azadC for 12 h, washed and allowed to recover for 12 h in the presence of 0.5 mM of APH. Replication
inhibition contributes to a reduction in chromosomal aberrations in both cell lines. Data show the mean and the SD from three independent
experiments. Differences were statistically significant (*P< 0.05, **P< 0.01 according Student’s t-test).
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FANCG-defective cells, it demonstrates that the sensitiza-
tion is mediated through inactivation of the FA–HR
pathway.
These results may have important clinical implications.
Resistance is a major difficulty with 5-azadC treatments,
and analogy can be made to melphalan resistance in
multiple myeloma. Melphalan is a crosslinker and binds
covalently to DNA and cause obstruction to oncoming
replication forks, replication collapse and DSBs, much
in the same matter as we demonstrate for 5-azadC.
Furthermore, FANCG-mutated cells are sensitive to
melphalan (37). Resistance to melphalan is demonstrated
to be mediated by increased HR by overexpression of
Fanconi’s anemia genes (38). Bortezomib is a proteasomal
inhibitor used in first line in combination with melphalan
to treat multiple myeloma (39). The mechanism of creat-
ing a clinical benefit with the combination of bortezomib
and melphalan is likely mediated by preventing resistance
through activation of the FA pathway to trigger HR
repair (40). Here, we suggest that bortezomib may be
useful in combination with 5-azadC, to prevent emerging
Figure 5. Proteasome and FA pathway work in the same route to
promote cell survival in 5-azadC-treated cells. AA8 and KO40 cells
were cotreated with 5-azadC and the proteasome inhibitor MG132
(0.1 mM) according to ‘Materials and Methods’ section. Then cultures
were allowed to grow (7–10 days) for analysis of colony-forming effi-
ciency (A). Data show that proteasome catalytic activity is necessary
for promoting cell survival of those cells treated with 5-azadC;
however, no evidence of sensitization was observed for KO40 cells.
Data were plotted as fold increase in cell death (B). Each bar represents
the mean and the SD from two independent experiments. Differences
were statistically significant (*P< 0.05, according Student’s t-test).
Figure 6. Inhibition of NHEJ protects from the deleterious effect
induced by 5-azadC. AA8 and KO40 cells in exponential growth
were plated at low density onto 10 cm Petri dishes and treated with
5-azadC in combination with NU7026 (10 mM) according to ‘Materials
and Methods’ section. Then cultures were allowed to grow (7–10 days)
for analysis of colony-forming efficiency (A). Data, plotted as fold
increase in cell survival, show that the increase in cell survival was
clearly higher for FANCG-deficient cells than for AA8 cells (B). Each
bar represents the mean and the SD from two independent experiments.
Differences were statistically significant (*P< 0.05, according Student’s
t-test).
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resistance. Indeed, a recent phase I clinical study
bortezomib was used in combination with 5-azadC in
AML patients, and a complete remission was observed
in 5 of 10 previously untreated patients (41), demonstrat-
ing that this may be an interesting future option that may
be tested.
Fanconi’s anemia patients often develop AML, and
treatment options are often limited owing to the intrinsic
sensitivity to DNA damaging agents. As 5-azadC is a more
modern and targeted treatment option, it may be suggested
as an alternative treatment to these patients. In one
reported case, a Fanconi’s anemia patient with an AML
derived from healthy donor cells received complete remis-
sion after a 5-azaC treatment (42). Although we do not
discourage, we would recommend cautious use of 5-
azadC in treatment of AML in Fanconi’s anemia
patients, as we show that cells defective in the Fanconi’s
anemia pathway are hypersensitive to 5-azadC.
Here, we demonstrate that 5-azadC causes replication-
associated DSBs, likely owing to DNMT–DNA adducts
obstructing replication fork progression, which in turn
trigger RAD51-mediated HR involving the Fanconi’s
anemia pathway. This likely represent an important cyto-
toxic mechanism for 5-azadC. However, our data are not
in disagreement with that 5-azadC may deplete DNMT
and reduce cancer burden through activation of genes in-
dependently of DNA damage.
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